Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Reevaluation of Clinical Trials Involving Selective RET Inhibitors for Thyroid Cancer Treatment

  • By

  • Yulu Zhou

  • Junjie Cao

  • Siqi Zhang

  • Mingjun Sun

  • Yaqi Zhang

  • Songzhe Li

  • Zining Luo

  • Pengyu Wang

  • Jiebin Xie

  • August 14, 2026

Share

Objective:

To correct the affiliations of author Pengyu Wang in the review and analysis of clinical trials of selective RET inhibitors for thyroid cancer treatment.

Approach:
  • Correction Details: The affiliation 'School of Engineering, China Pharmaceutical University, Nanjing, China' for author Pengyu Wang has been removed, and 'Independent Researcher, Xianning, China' has been added.
Key Findings:
  • The original paper incorrectly listed the affiliation of author Pengyu Wang.
  • The updated paper reflects the correct affiliation for Pengyu Wang.
Interpretation:

The article has been updated to accurately represent the author's affiliation.

Conclusion:

The original version of the article has been corrected.

Sources:

Original Source(s)

Correction: Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer

  • by Yulu Zhou, Junjie Cao, Siqi Zhang, Mingjun Sun, Yaqi Zhang, Songzhe Li, Zining Luo, Pengyu Wang, Jiebin Xie

  • August 14, 2026

Related Content

Correction: Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer

National Cancer Institute–Supported Obesity and Cancer Research, 2015-2022

Expanding the donor pool in secondary AML: a step forward, with caveats